International Nonproprietary Name
On March 20, 2018, Antibe Therapeutics announced successful results for Phase 2B gastrointestinal safety study for ATB-346. On June 1, 2020, Antibe announced positive results for ATB-346 (now known by its International Nonproprietary Name, otenaproxesul) in its final Phase 2 trial, a dose ranging, efficacy study. The company's second drug, an opioid-replacement for post-surgical pain, is expected to start clinical trials in late 2021.